CMF adjuvant programs at the Milan Cancer Institute.

CMF adjuvant programs at the Milan Cancer Institute. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

CMF adjuvant programs at the Milan Cancer Institute. Abstract Text:

G Bonadonna,A Rossi,G Tancini,P Valagussa,U Veronesi,

CMF adjuvant programs at the Milan Cancer Institute. Publishing Authors By Initials

G Bonadonna,A Rossi,G Tancini,P Valagussa,U Veronesi,

For similar diagnosis: prognosis research abstracts see: diagnosis: prognosis research

PUBMED ID PMID:

MEDLINE DATE:

CMF adjuvant programs at the Milan Cancer Institute. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 96

Page Numbers: 66-73

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 1984

CMF adjuvant programs at the Milan Cancer Institute. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 44671

CMF adjuvant programs at the Milan Cancer Institute. Keywords Mesh Terms:

KEYWORDS: Prognosis

MESH TERMS: administration & dosage

Chemical & Substance for Abstract: CMF adjuvant programs at the Milan Cancer Institute. Information

Substance Name: Methotrexate

Registry Number: 59-05-2

Grant and Affiliation Information for CMF adjuvant programs at the Milan Cancer Institute.

AFFILIATION:

Country: GERMANY, WEST

AGENCY: United States NCI

GRANT: N01-CM-33714

ACRONYM: CM

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

CMF adjuvant programs at the Milan Cancer Institute Related Publications

• Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program.
• CMF adjuvant programs at the Milan Cancer Institute.
• Can axillary and supraclavicular radiotherapy be avoided after breast-conserving surgery and axillary dissection in women with multiple involved axillary nodes? Experience at the European Institute of Oncology.
• Efficacy of hCG and GnRH for inducing ovulation in the jenny.
• Electrolytes changes in mammary secretions before foaling in jennies.
• Electron intraoperative treatment in patients with early-stage breast cancer: data update.
• Genetic diversity, structure and marker-trait associations in a collection of Italian tomato (Solanum lycopersicum L.) landraces.
• HRT opposed to low-dose tamoxifen (HOT study): rationale and design.
• Influence of age and foaling on plasma protein electrophoresis and serum amyloid A and their possible role as markers of equine neonatal septicaemia.
• Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer.
• Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution.
• Luteal function in jennies following PGF(2alpha) treatment 3 days after ovulation.
• Morphological features of the placenta at term in the Martina Franca donkey.
• Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: the Milan Institute experience.
• Nanosize titanium dioxide stimulates reactive oxygen species in brain microglia and damages neurons in vitro.
• New adjuvant trials for resectable breast cancer at the Istituto Nazionale Tumori of Milan.
• New trends in the treatment of breast cancer at the Cancer Institute of Milan.
• Paradigm changes in medical science.
• Particulate matter, oxidative stress and neurotoxicity.
• Producing a caring environment for staff: forging old paradigms.
• Regional lymph node dissection in melanoma of the limbs. Stage I. A cooperative international trial (WHO Collaborating Centers for diagnosis and treatment of melanoma).
• Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence.
• Sentinel lymph node biopsy in male patients with early breast cancer.
• The cellular and genomic response of an immortalized microglia cell line (BV2) to concentrated ambient particulate matter.
• The control of breast cancer: a look into the future.
• The effects of a nitrogen mustard derivative of phenylalanine on experimental tumours.
• Unnecessary axillary node dissections in the sentinel lymph node era.
• When Sentinel Lymph Node is Intramammary.
• Where will your attitude take you today.
• [Neoplastic transformation of cutaneous cysts; incidence, morphological aspect, pathogenesis, case reports.]